FIELD: medicine. SUBSTANCE: method involves applying muteins of specific wild type of cytokin being its receptor antagonists as immunogens for inducing antibody formation against this cytokin of disk type to enable its level normalization in the cases of diseases caused by its excessive synthesis. EFFECT: avoided states caused by mutein interleukin-6 excessive production. 11 cl, 6 dwg, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
| NUCLEIC ACID SYNTHETIC MOLECULE (VERSIONS), MAMMAL CELL EXPRESSION VECTOR, MAMMAL HOST CELL AND METHOD OF EXPRESSING ANTIGEN PROTEIN OF HUMAN EPIDERMAL GROWTH FACTOR-2 (HER2/neu) OR SHORTENED FORM THEREOF | 2004 |
|
RU2397249C2 |
| METHOD OF OLIGOPEPTIDE PRODUCING | 1994 |
|
RU2136697C1 |
| FUSED PROTEIN OF TELOMERASE REVERSE TRANSCRIPTASE, NUCLEOTIDES CODING THEM, AND USING THEM | 2007 |
|
RU2473691C2 |
| METHOD OF IN VITRO REPRODUCTION OF PROTEOLYTIC ACTIVITY OF HEPATITIS C VIRUS PROTEASE NS3 | 1995 |
|
RU2149185C1 |
| NEW Tat-COMPLEXES AND VACCINES CONTAINING THEM | 2005 |
|
RU2432356C2 |
| PYRIDINONE PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | 2007 |
|
RU2472782C2 |
| INTERLEUKIN-1 CONJUGATES AND THEIR APPLICATION | 2006 |
|
RU2441067C2 |
| PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | 2008 |
|
RU2490265C2 |
| NUCLEOTIDE SEQUENCE EXPRESSING ANCHOR PROTEIN OF EXOSOMES FOR USE AS VACCINE | 2017 |
|
RU2761642C2 |
